Randomized dose-escalation designs for drug combination cancer trials with immunotherapy

References

• Aglietta, M., C.Barone, M., Sawyer, M., Moore, W., Miller, J., Bagalà, F., Colombi, C., Cagnazzo, Gioeni, L., Wang, E., et al. (2014). A phase i dose escalation trial of tremelimumab (cp-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. Annals of Oncology 25(9): 1750–1755. doi:10.1093/annonc/mdu203.
   PubMed Web of Science ®Google Scholar
• Bornkamp, B. (2017). Dose-finding studies in Phase II: Introduction and overview. In J. O’Quigley, A. Iasonos, B. Bornkamp (Eds.), Handbook of Methods for Designing, Monitoring, and Analyzing Dose-Finding Trials, Vol. Chapter 11. 189–204. 6000 Broken Sound Parkway NW, Suite 300, CRC Press, Taylor and Francis Group.
   Google Scholar
• Crane, C. H., Abbruzzese, J. L., Evans, D. B., Wolff, R. A., Ballo, M. T., Delclos, M., Milas, L., Mason, K., Charnsangavej, C., Pisters, P., et al. (2002). Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? International Journal of Radiation Oncology Biology Physics 52(5): 1293–1302. doi:10.1016/S0360-3016(01)02740-7.
   PubMed Web of Science ®Google Scholar
• Dahlberg, S. E., Shapiro, G. I., Clark, J. W., Johnson, B. E. (2014). Evaluation of statistical designs in phase i expansion cohorts: The dana-farber/harvard cancer center experience. JNCI: Journal of the National Cancer Institute 106(7):dju163. doi:10.1093/jnci/dju163.
   PubMedGoogle Scholar
• Disis, M. L. (2010). Immune regulation of cancer. Journal of Clinical Oncology 28(29):4531–4538. doi:10.1200/JCO.2009.27.2146.
   PubMed Web of Science ®Google Scholar
• Hellmann, M. D., Rizvi, N. A., Goldman, J. W., Gettinger, S. N., Borghaei, H., Brahmer, J. R., Ready, N. E., Gerber, D. E., Chow, L. Q., Juergens, R. A., et al. (2017). Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (checkmate 012): Results of an open-label, phase 1, multicohort study. The Lancet Oncology 18(1): 31–41. doi:10.1016/S1470-2045(17)30072-4.
   PubMed Web of Science ®Google Scholar
• Iasonos, A., Wages, N. A., Conaway, M. R., Cheung, K., Yuan, Y., O’Quigley, J. (2016). Dimension of model parameter space and operating characteristics in adaptive dose-finding studies. Statistics in Medicine 35(21):3760–3775. doi:10.1002/sim.6966.
   PubMed Web of Science ®Google Scholar
• Ivanova, A., Wang, K. (2004). A non-parametric approach to the design and analysis of two-dimensional dose-finding trials. Statistics in Medicine 23(12):1861–1870. doi:10.1002/(ISSN)1097-0258.
   PubMed Web of Science ®Google Scholar
• Kyi, C., Postow, M. A. (2014). Checkpoint blocking antibodies in cancer immunotherapy. FEBS letters 588(2):368–376. doi:10.1016/j.febslet.2013.10.015.
   PubMed Web of Science ®Google Scholar
• Lin, R., Yin, G. (2017). Bayesian optimal interval design for dose finding in drug-combination trials. Statistical Methods in Medical Research 26(5):2155–2167. doi:10.1177/0962280215598665.
   PubMed Web of Science ®Google Scholar
• Neuenschwander, B., Branson, M., Gsponer, T. (2008). Critical aspects of the Bayesian approach to phase i cancer trials. Statistics in Medicine 27(13):2420–2439. doi:10.1002/sim.3348.
   PubMed Web of Science ®Google Scholar
• O’Quigley, J., Paoletti, X., Maccario, J. (2002). Non-parametric optimal design in dose finding studies. Biostatistics 3(1):51–56. doi:10.1093/biostatistics/3.1.51.
   PubMed Web of Science ®Google Scholar
• O’Quigley, J., Pepe, M., Fisher, L. (1990). Continual reassessment method: A practical design for phase 1 clinical trials in cancer. Biometrics 33–48. doi:10.2307/2531628.
   PubMed Web of Science ®Google Scholar
• O’Quigley, J., Shen, L. Z. (1996). Continual reassessment method: A likelihood approach. Biometrics 673–684. doi:10.2307/2532905.
   PubMed Web of Science ®Google Scholar
• O’Quigley, J., Zohar, S. (2010). Retrospective robustness of the continual reassessment method. Journal of Biopharmaceutical Statistics 20(5):1013–1025. doi:10.1080/10543400903315732.
   PubMed Web of Science ®Google Scholar
• Oron, A. P., Hoff, P. D. (2013). Small-sample behavior of novel phase i cancer trial designs. Clinical Trials 10(1):63–80. doi:10.1177/1740774512469311.
   PubMed Web of Science ®Google Scholar
• Paller, C. J., Bradbury, P. A., Ivy, S. P., Seymour, L., LoRusso, P. M., Baker, L., Rubinstein, L., Huang, E., Collyar, D., Groshen, S., et al. (2014). Design of phase i combination trials: Recommendations of the clinical trial design task force of the nci investigational drug steering committee. Clinical Cancer Research 20(16): 4210–4217. doi:10.1158/1078-0432.CCR-13-3045.
   PubMed Web of Science ®Google Scholar
• Pardoll, D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews. Cancer 12(4):252. doi:10.1038/nrc3239.
   PubMed Web of Science ®Google Scholar
• Patnaik, A., Kang, S. P., Rasco, D., Papadopoulos, K. P., Elassaiss-Schaap, J., Beeram, M., Drengler, R., Chen, C., Smith, L. S., Espino, G., et al. (2015). Phase I Study of Pembrolizumab (Mk-3475; Anti-Pd-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clinical Cancer Research, clincanres–2607.
   Google Scholar
• R Core Team. (2015). R: A Language and Environment for Statistical Computing. Vienna, Austria:R Foundation for Statistical Computing.
   Google Scholar
• Reiner, E., Paoletti, X., O’Quigley, J. (1999). Operating characteristics of the standard phase i clinical trial design. Computational Statistics & Data Analysis 30(3):303–315. doi:10.1016/S0167-9473(98)00095-4.
   Web of Science ®Google Scholar
• Riviere, M.-K., Dubois, F., Zohar, S. (2015). Competing designs for drug combination in phase i dose-finding clinical trials. Statistics in Medicine 34(1):1–12. doi:10.1002/sim.v34.1.
   PubMed Web of Science ®Google Scholar
• Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., Weber, J. S., Joshua, A. M., Hwu, W.-J., Gangadhar, T. C., et al. (2014). Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. The Lancet 384(9948): 1109–1117. doi:10.1016/S0140-6736(14)60958-2.
   PubMed Web of Science ®Google Scholar
• Saad, E. D., Paoletti, X., Burzykowski, T., Buyse, M. (2017). Precision medicine needs randomized clinical trials. Nature Reviews Clinical Oncology 14(5):317–323. doi:10.1038/nrclinonc.2017.8.
   PubMed Web of Science ®Google Scholar
• Sharma, P., Allison, J. P. (2015). The future of immune checkpoint therapy. Science 348(6230):56–61. doi:10.1126/science.aaa5139.
   PubMed Web of Science ®Google Scholar
• Sweeting, M., Mander, A., Sabin, T., et al. (2013). Bcrm: Bayesian continual reassessment method designs for phase i dose-finding trials. Journal of Statistical Software 54(1): 1–26. doi:10.18637/jss.v054.i13.
   Google Scholar
• Wages, N. A., Conaway, M. R., O’Quigley, J. (2011). Continual reassessment method for partial ordering. Biometrics 67(4):1555–1563. doi:10.1111/j.1541-0420.2011.01560.x.
   PubMed Web of Science ®Google Scholar
• Whitehead, J., Williamson, D. (1998). Bayesian decision procedures based on logistic regression models for dose-finding studies. Journal of Biopharmaceutical Statistics 8(3):445–467. doi:10.1080/10543409808835252.
   PubMedGoogle Scholar
• Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., Kelley, S. (2006). Discovery and development of sorafenib: A multikinase inhibitor for treating cancer. Nature Reviews. Drug Discovery 5(10):835. doi:10.1038/nrd2130.
   PubMed Web of Science ®Google Scholar
• Yamamoto, N., Nokihara, H., Yamada, Y., Shibata, T., Tamura, Y., Seki, Y., Honda, K., Tanabe, Y., Wakui, H., Tamura, T. (2017). Phase i study of nivolumab, an anti-pd-1 antibody, in patients with malignant solid tumors. Investigational New Drugs 35(2):207–216. doi:10.1007/s10637-016-0411-2.
   PubMed Web of Science ®Google Scholar
• Yin, G., Yuan, Y. (2009). Bayesian dose finding in oncology for drug combinations by copula regression. Journal of the Royal Statistical Society: Series C (Applied Statistics) 58(2):211–224. doi:10.1111/rssc.2009.58.issue-2.
   Google Scholar